SCHEMBL25023972

SCHEMBL25023972

Cc1cnc(C(=O)c2ccnc3[nH]ccc23)c(NS(=O)(=O)c2cc(C)c(Cl)c(C(F)(F)F)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.64
CCR2 P41597 4/20 0.63
CYP2C9 P11712 2/20 0.54
NUDT1 P36639 1/20 0.35
SLC40A1 Q9NP59 1/20 0.34
JAK1 P23458 1/20 0.33
AXL P30530 1/20 0.33
PRKCI P41743 1/20 0.33
MET P08581 1/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
HSP90AA1 P07900 1/20 0.33
RAB9A P51151 1/20 0.33
ADAM17 P78536 1/20 0.33
KMT2A Q03164 1/20 0.33
KLF5 Q13887 1/20 0.33
TSHR P16473 1/20 0.33
ACLY P53396 1/20 0.32
MAP3K7 O43318 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1762385 0.89 CYP3A4 (0.79) CYP3A4CCR2CYP2C9JAK1TSHR
SCHEMBL22461745 0.89 CYP3A4 (0.67) CYP3A4CCR2CYP2C9NUDT1JAK1
SCHEMBL306072 0.86 CYP2C9 (0.65) CYP3A4CCR2CYP2C9CYP2C19
SCHEMBL26066327 0.84 CYP3A4 (0.56) CYP3A4CCR2CYP2C9NUDT1CYP2C19
SCHEMBL306637 0.83 CYP2C9 (0.77) CYP3A4CCR2CYP2C9TSHR
SCHEMBL12594251 0.82 CYP3A4 (0.63) CYP3A4CCR2CYP2C9NUDT1CYP2C19
SCHEMBL1762442 0.82 CYP2C9 (0.64) CYP3A4CCR2CYP2C9
SCHEMBL12594373 0.81 CYP2C9 (0.55) CYP3A4CCR2CYP2C9NUDT1AXL
SCHEMBL1762314 0.80 CYP2C9 (0.58) CYP3A4CCR2CYP2C9NUDT1CYP2C19
SCHEMBL22461660 0.80 CYP2C9 (0.65) CYP3A4CCR2CYP2C9JAK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134080-A1 CCR2 INHIBITORS FOR USE IN TREATING RENAL DISEASES ChemoCentryx, Inc. (US) 2023-02-15 EP disclosed